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Abstract 
Background: Understanding the in vivo size-dependent pharmacokinetics and toxicity of nanoparticles is crucial to 
determine their successful development. Systematic studies on the size-dependent biological effects of nanoparticles 
not only help to unravel unknown toxicological mechanism but also contribute to the possible biological applications 
of nanomaterial.
Methods: In this study, the biodistribution and the size-dependent biological effects of  Fe3O4@SiO2–NH2 nanoparti-
cles (Fe@Si-NPs) in three diameters (10, 20 and 40 nm) were investigated by ICP-AES, serum biochemistry analysis and 
NMR-based metabolomic analysis after intravenous administration in a rat model.
Results: Our findings indicated that biodistribution and biological activities of Fe@Si-NPs demonstrated the obvi-
ous size-dependent and tissue-specific effects. Spleen and liver are the target tissues of Fe@Si-NPs, and 20 nm of Fe@
Si-NPs showed a possible longer blood circulation time. Quantitative biochemical analysis showed that the alterations 
of lactate dehydrogenase (LDH) and uric acid (UA) were correlated to some extent with the sizes of Fe@Si-NPs. The 
untargeted metabolomic analyses of tissue metabolomes (kidney, liver, lung, and spleen) indicated that different sizes 
of Fe@Si-NPs were involved in the different biochemical mechanisms. LDH, formate, uric acid, and GSH related metab-
olites were suggested as sensitive indicators for the size-dependent toxic effects of Fe@Si-NPs. The findings from 
serum biochemical analysis and metabolomic analysis corroborate each other. Thus we proposed a toxicity hypoth-
esis that size-dependent NAD depletion may occur in vivo in response to nanoparticle exposure. To our knowledge, 
this is the first report that links size-dependent biological effects of nanoparticles with in vivo NAD depletion in rats.
Conclusion: The integrated metabolomic approach is an effective tool to understand physiological responses to the 
size-specific properties of nanoparticles. Our results can provide a direction for the future biological applications of 
Fe@Si-NPs.
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Background
Iron oxide nanoparticles (IONPs) are magnetic, relatively 
non-toxic and highly biocompatible, thus giving IONPs 
potential biomedical applications in a wide range of fields 
such as diagnostic imaging [1–3], drug delivery [4], gene 
therapy [5], magnetic nanoparticle separation [6], in vivo 
cell tracking [7], or as iron supplement for the treatment 
of metal poisoning [8]. However, due to the high sur-
face energies and the magnetic dipole–dipole attractions 
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between the nanoparticles, IONPs are highly prone to 
agglomeration under physiological conditions and non-
specific adsorption of biomolecules [9]. Coating IONPs 
with silica is considered as an effective means to solve 
their dispersibility and adsorption [10]. Silica-coated 
core–shell nanoparticles showed sevenfold clearer con-
trasts in magnetic resonance imaging than simple nano-
particles [11]. However, it has been proved that silanol 
groups on the plain silica coated IONPs play a major role 
in nanoparticle-cell interactions and cause membrane 
protein degradation and intracellular free radical produc-
tion [12, 13]. Thus numerous surface functionalization 
methods have been introduced to improve the biocom-
patibility of silica-coated IONPs.
Recently, amino-functionalized  Fe3O4@SiO2 nanopar-
ticles (Fe@Si-NPs), taking advantage of their functional 
synergistic effects from the different components, dem-
onstrated outstanding biocompatibility and special mag-
netic properties compared with the existing  Fe3O4@SiO2 
nanoparticles [14, 15]. The silica shells not only prevent 
the oxidation and agglomeration of magnetic core at 
physiological conditions but also enhance their chemi-
cal stability. The amino modifications of the silica sur-
face decrease the detrimental interactions with cellular 
membranes and prolong the blood circulation time after 
in vivo administration. Studies have shown that the func-
tionalized silanol moieties with amino groups on the sur-
face of silica-coated IONPs can effectively reduce toxicity 
both in  vitro and in  vivo, and render the nanoparticle 
great biocompatibility [16]. Thus, they show promising 
biological applications such as biomedical imaging, gene 
delivery, and drug transport [12, 16].
Besides the surface modification and chemistry, the 
particle size is also a significant factor for tuning the 
biodistribution and the potential toxicity of nanopar-
ticles, which can deeply affect their pharmacokinetics, 
namely absorption and internalization, biodistribution, 
metabolic fate and elimination from the body, as well 
as their performance. As a rule of thumb, nanoparticles 
between 10 and 100 nm in diameter can avoid prompt 
spleen, liver and kidney filtration, and extend the blood 
circulation time and increase the access of nanopar-
ticles to the targeted organ. The biodistribution and 
accumulation of iron oxide nanoparticles in various tis-
sues/organs can be indirectly evaluated by the determi-
nation of whole iron content using inductively coupled 
plasma spectroscopy or Prussian blue staining [17]. On 
the other hand, due to their intrinsic complexity, most 
of the toxicity results of core–shell IONPs are based 
on in  vitro assays, e.g. Urbas et  al. [18] demonstrated 
that IONP size around 100  nm can affect cell metab-
olism, while Majeed et  al. [19] reported that IONPs 
with sizes around 10–20 nm do not have obvious toxic 
effect. Although these researches provided useful pre-
liminary information and suggested that toxicities are 
in inverse proportion to the size of nanoparticles, these 
results may not be applicable for all the other cell types 
or organs in the body [17, 20]. Most importantly, there 
is lack of correlation between the in  vivo biodistribu-
tion and the in vitro toxic effects, and there is no clear 
understanding of the size effect in vivo.
Drugs or toxins can cause the concentration variations 
of endogenous metabolites and thus shift the fluxes of 
metabolic pathways. Monitoring the metabolic changes 
in different organs will provide direct information on 
the functioning of biochemical pathways and the pos-
sible harmful effects of these nanoparticles. Therefore a 
detailed metabolic response of different size core–shell 
IONPs in organs is of prime importance for next phase of 
clinical studies. In drug discovery process, metabolomic 
analysis can be used to monitor drug side-effect and 
metabolism, identify biomarkers, explore the mechanism 
of action, and provide the feedback on the tissue-speci-
ficity [21]. It has been proved to be an effective method to 
evaluate the nanotoxicity in the previous study [22].
After completing the evaluation of the subchronic toxic 
effects of 20 nm Fe@Si-NPs, we obtained the information 
on dose selection, one critical factor in developing bio-
medical nanomaterials [23]. However, the size effects of 
Fe@Si-NPs, another critical factor associated with toxic-
ity, still need to be assessed. The in vivo performance of 
IONPs usually achieved optimization in dozens of min-
utes or hours following intravenous injection, and the 
potential adverse effects of contrast agent administra-
tion, such as post-contrast acute kidney injury (PC-AKI), 
mainly occur within 48 h after injection [24]. This means 
that the first 48 h is critical for toxicological assessment. 
Therefore, we chose 48  h and 6  h (an early stage of the 
acute-phase response) to investigate the acute toxic 
effects of Fe@Si-NPs.
On toxicokinetics, previous report showed that the 
small IONPs (around 10 nm) were more easily taken up 
by the liver and rapidly cleared by kidneys, while the large 
IONPs (around 40  nm) mainly by the spleen [25]. The 
diameters of the related commercial products are usu-
ally of about 20 nm, such as Feridex (< 30 nm) and Reso-
vist (around 17 nm). In this study, in view of the different 
structure between IONPs and Fe@Si-NPs, we chose the 
bilateral sizes (10 nm and 40 nm) of the typical diameter 
of IONPs (20  nm) for optimization. A combined analy-
sis of serum biochemical parameters, metabolomic data 
and the iron content of the target tissues was applied to 
uncover the correlation between biodistribution and 
acute toxic effects of Fe@Si-NPs, provide comprehensive 
and complementary insights into their size effects in vivo, 
and lead to toxicity hypothesis generation.
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Materials and methods
Synthesis and characterization of core–shell structured 
nanoparticles
Fe@Si-NPs were prepared by following the multistep 
synthetic procedure as reported previously [14]. Briefly, 
in the first step, monodisperse magnetic  Fe3O4 cores 
(around 2.3 to 4.0 nm in diameter) were synthesized by 
a modified solvothermal method. In the second step, 
according to the Stober method, three different thick-
nesses of silica shell were coated on the magnetic core by 
adjusting the concentration ratio of ammonium to tetra-
ethyl orthosilicate [26]. In the third step, the obtained 
core–shell structures of three different sizes (around 10, 
20  nm, and 40  nm in diameter) were respectively func-
tionalized with N-(2-aminoethyl)-3-aminopropyl tri-
methoxysilane (AEAPS) to introduce amino groups by 
sol–gel co-condensation method. Afterward the precipi-
tate was collected, washed, dried in vacuum, and charac-
terize by TEM (Additional file 1: Figure S1). Before use, 
Fe@Si-NPs were freshly well-dispersed by ultrasound in 
saline solution.
Animal handling and biological sample collection
All animals involved in this study were cared for accord-
ing to the principles of the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and 
approved by the Ethical and Research Committee of Xia-
men University (SYXK 2013-0006). All animal experi-
ments were performed at specific pathogen free (SPF) 
facility of Xiamen University Laboratory Animal Center 
(XMULAC). A total of 52 9-week-old male Sprague Daw-
ley rats (258 ± 10  g) were used in our study. The envi-
ronment conditions were set at 21–26 °C with a relative 
humidity of 45–70%, and a 12/12-h light/dark cycle. Food 
and tap water were provided ad libitum. After 2 week of 
acclimatization, these 52 rats were randomly assigned 
to four groups (control group, 10 nm, 20 nm, and 40 nm 
Fe@Si-NPs-exposure groups, 13 rats each group), and 
a single dose of Fe@Si-NPs in saline was administrated 
intravenously to the rats at dose of 1  mg Fe/kg body 
weight (b. w.). Control group was treated with saline only. 
Animals were sacrificed by exsanguination under isoflu-
rane anesthesia at time point on 6 h (5 rats each group) 
post-dose (p. d.) and 48 h (8 rats each group) p. d. Blood 
sample (1 mL) was collected for serum biochemical pro-
file analysis. Kidney, liver, lung, and spleen tissues were 
excised in duplicate and snap-frozen in liquid nitrogen 
for tissue extraction and ICP-AES analysis. These sam-
ples were stored at − 80 °C until use.
Serum biochemical analysis
Standard spectrophotometric methods were carried out 
to measure the following biochemical parameters on a 
Roche Modular P800 automatic analyzer (Roche Diag-
nostics, Germany): total protein (TP), albumin (Alb), 
globulin (Glo), Alb/Glo, total bilirubin (Tbil), direct bili-
rubin (Dbil), indirect bilirubin (Ibil), alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), AST/
ALT, gamma glutamyltransferase (GGT), alkaline phos-
phatase (ALP), triglycerides (TG), total cholesterol (TC), 
high density lipoprotein (HDL), low density lipopro-
tein (LDL), glucose (Glu), lactate dehydrogenase (LDH), 
blood urea nitrogen (Bun), creatinine (Cn), Bun/Cn, uric 
acid (UA), and total bile acid (TBA). All parameters are 
expressed as mean ± standard deviation (SD).
Sample preparation and 1H NMR spectroscopic analysis
The method for the extraction of polar metabolites was 
established by previous researchers [27]. In brief, pre-
weighed kidney, liver, lung, or spleen sample (100  mg) 
was homogenized in 400 μL of  CH3OH and 85 μL of  H2O 
at 4 °C. The homogenates were transferred into a 2.5-mL 
tube, and mixed with 400 μL of  CHCl3 and 200 μL of  H2O 
and vortexed for 60  s. After 10 min partitioning on ice, 
the samples were centrifuged for 5 min (10,000×g, 4 °C). 
The upper supernatants were transferred into 1.5  mL 
tubes, and lyophilized to remove  CH3OH and  H2O. The 
extracts were reconstituted in 0.5  mL  D2O containing 
1 mM TSP, then transferred into 5 mm NMR tubes and 
analyzed by NMR spectroscopy. 1H NMR spectra of these 
samples were acquired on a Bruker-AV600 spectrometer 
at 296  K. Standard 1D 1H spectra were acquired with a 
NOESPYPR1D pulse sequence. For each sample, 64 FIDs 
were collected into 32 K data points over a spectral width 
of 12 kHz with a relaxation delay of 6.5 μs and an acquisi-
tion time of 2.66 s.
Spectral processing and data multivariate analyses
The FIDs were multiplied by an exponential function 
corresponding to a 1  Hz line-broadening factor before 
Fourier transform to increase the signal-to-noise ratio. 
The acquired NMR spectra were manually phase- and 
baseline-corrected using MestReNova (V9.0, Mestrelab 
Research, Santiago de Compostela, Galicia, Spain) and 
referenced to TSP at δ 0.00 for tissue extract samples. The 
segments of δ 5.12–4.57 and δ 3.37–3.35 in the spectra 
were excluded to remove variation in residual water and 
methanol signal. The remainder spectral region δ 9.5–0.5 
was segmented into regions of 0.001 ppm. Normalization 
was applied to the data from each sample, which made 
the data directly comparable with each other.
SIMCA v14.0 (Umetrics, Umea, Sweden) was served to 
multivariate statistical analysis. Unsupervised principal 
component analysis (PCA) was performed using a mean-
centered scaling to verify the quality of spectra and visu-
alize the grouping of the samples. Supervised orthogonal 
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partial least-squares discriminant analysis (OPLS-DA) 
was carried out at a Pareto scaling to identify differences 
between groups.
The results were visualized in the forms of scores plots 
to show the separation between groups and volcano plots 
to visualize − log2 of fold changes in concentration on the 
x-axis versus the − log10 of the P-value on the y-axis. In 
the volcano plots, the color was associated with the cor-
relation coefficients, hot color for strong correlation, and 
cool color for weak correlation, and the size of dot was 
associated to VIP value. Both the correlation coefficients 
and VIP values were derived from OPLS-DA. Positive 
 log2 values of fold changes stand for the metabolites in up 
in comparison to the control group.
The cutoff levels for correlation coefficients, VIP val-
ues, and P-values for the univariate statistical analysis 
were | r | > 0.666 (the degree of freedom equals to 4), the 
top 20% of all VIP scores, and P value < 0.05, respectively. 
The metabolites, met at least two of three criteria, were 
selected as the discriminatory ones.
Statistical analysis
Statistical analyses were performed using SPSS software 
(version 21.0 for Windows; SPSS, Inc., Chicago, IL, USA). 
Significant differences between the experimental groups 
and corresponding control group were analyzed by using 
the unpaired two-tailed Student’s t-test. The P values less 
than 0.05 were considered statistically significant. The 
results were expressed as mean ± SD.
Results
Effects of nanoparticle size on iron biodistribution 
in tissues of Fe@Si‑NPs
We employed ICP-AES to determine the iron con-
centration in tissues as an indirect assessment for the 
biodistribution of Fe@Si-NPs. On the whole, as shown 
in Fig.  1, the highest uptakes of all the three sizes of 
nanoparticles were concentrated in spleen and liver at 
6 h p.d., whereas the iron contents of spleen and liver 
in the mid- and large-size groups displayed a signifi-
cant decrease at 48 h p.d. The kidney uptake of small-
size and large-size Fe@Si-NPs took place at 48  h p.d., 
while the mid-size Fe@Si-NPs showed no tissue specific 
infiltration at 48 h p.d. suggesting that they would have 
longer blood circulation time.
The iron contents of liver in the small-, mid- and 
large-size groups were increased to 135% (P < 0.05), 
140% (P < 0.05), and 161% (P < 0.05), and those of spleen 
were increased to 169% (P < 0.05), 153% (P < 0.05) and 
143% (P < 0.05) of the corresponding controls, respec-
tively. However, no significant distribution difference 
of iron in kidneys and lung was observed at 6  h p. d. 
At 48  h p. d., the iron content of kidney in the small- 
and large-size groups was increased to 176% (P < 0.05) 
and 159% (P < 0.05) of the controls, respectively, and 
the iron content in liver (small-size group), lung (large-
size group) and spleen (small-size group) was increased 
to 217% (P < 0.05), 128% (P < 0.05) and 188% (P < 0.05) 
of the controls, respectively, but no significant distri-
bution difference of iron contents in other groups was 
observed. These results suggest that all three sizes of 
Fe@Si-NPs tend to accumulate in the liver and spleen at 
6 h p. d., however, 48 h after treatment, the small-size 
Fe@Si-NPs are sequestered not only by liver and spleen 
but also by kidneys; and the large-size ones reach kid-
ney and lung.
In addition, there was no statistically significant dif-
ference in the ratio of the tissue weight to the total body 
weight of rats between all Fe@Si-NPs-treated groups 
and the corresponding controls (Additional file  1: Fig-
ure S2). Thus, the iron concentration measured with 
ICP-AES positively correlative to the biodistribution 
and tissue retention of Fe@Si-NPs. In addition, no 
apparent pathological change was observed in the kid-
ney, lung, liver and spleen (Additional file 1: Figure S3).
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Fig. 1 Biodistribution of Fe in the different tissues in the different dose groups at 6 h and 48 h post-administration of Fe@Si-NPs. C, control group; S, 
small-size group; M, mid-size group; L, large-size group; 6, 6 h post-dose; 48, 48 h post-dose. *Significant differences between treatment and control 
groups as judged by Student’s t-test (*P < 0.05)
Page 5 of 14Li et al. J Nanobiotechnol          (2019) 17:124 
Effects of nanoparticle size of Fe@Si‑NPs on the serum 
biochemical parameters
There are a wide variety of substances in serum, includ-
ing proteins, enzymes, lipids, metabolites etc. Testing 
for these substances provides information on the func-
tional status of tissues in the body. In this study, serum 
biochemical analyses were performed to quantitatively 
evaluate the effects of three different size nanoparticles 
exposure on rats. Table  1 shows that the levels of Glo, 
Alb/Glo, Ibil, AST/ALT, TG, TC, LDL-C, Glc, LDH, 
BUN, Cn, BUN/Cn, and UA in rat sera in some treatment 
groups changed distinctly compared to the correspond-
ing controls, however, only the changes of LDH and UA 
levels were, respectively negatively and positively, cor-
related with the sizes of Fe@Si-NPs to some extent. As 
shown in Table 1, a decrease of LDH levels to 87%, 63% 
(P < 0.001), and 48% (P < 0.001) of the controls at 6  h p. 
d., and 88%, 69%, and 66% of the controls at 48  h p. d. 
was observed in small-, mid- and large-size Fe@Si-NPs 
treated groups, respectively. On the contrary, an increase 
of UA levels to 140% (P < 0.001), 164% (P < 0.001), and 
173% (P < 0.001) of the controls at 6  h p. d., and 116%, 
138% (P < 0.001), and 127% (P < 0.05) of the controls at 
48 h p. d. was observed in small-, mid- and large-size Fe@
Si-NPs treated groups, respectively.
H NMR spectral profiles and metabolic characteristics 
of tissues from rats
Representative 1H NMR spectra of tissue extracts includ-
ing kidney, liver, lung and spleen are shown in Fig. 2. The 
primary peaks in the spectra were assigned to specific 
metabolites (Additional file 1: Table S1) according to pre-
vious studies [22, 23], and confirmed by a public NMR 
database (Human Metabolome Database V3.0, see www.
hmdb.ca) and an in-house developed NMR database. 
Different tissues demonstrate their own unique spectral 
profiles, which provide the characteristic biochemical 
alterations corresponding to the specific tissues following 
the administration of Fe@Si-NPs.
To get the overall metabolic information and exam-
ine the intrinsic variation within the respective bio-
compartment, supervised OPLS-DA models on the 
Table 1 Effect of  Fe3O4@SiO2–NH2 nanoparticle administration on blood biochemical indexes
TP total protein, Alb albumin, Glo globulin, Tbil total bilirubin, Dbil direct bilirubin, Ibil indirect bilirubin, ALT alanine aminotransferase, AST aspartate aminotransferase, 
GGT gamma glutamyltransferase, ALP alkaline phosphatase, TG triglycerides, TC total cholesterol, HDL high-density lipoprotein, LDL low-density lipoprotein, Glc 
glucose, LDH lactate dehydrogenase, BUN blood urea nitrogen, Cn creatinine, UA uric acid, TBA total bile acid
* Significant differences between treatment and control groups as judged by Student’s t-test using SPSS (*P < 0.05; **P < 0.001)
a C, control group; S, small-size group (around 10 nm in diameter); M, mid-size group (around 20 nm in diameter); L, large-size group (around 40 nm in diameter); 6, 
6 h post-dose; 48,48 h post-dose
b Each value data represents the mean ± S.D
Indexes C6a S6 M6 L6 C48 S48 M48 L48
TP (g/L) 54.96 ± 2.18b 55.44 ± 2.29 57.56 ± 3.38 57.62 ± 1.60 55.53 ± 1.98 56.71 ± 2.36 55.04 ± 2.26 56.30 ± 3.59
Alb (g/L) 30.66 ± 1.01 30.54 ± 0.74 30.98 ± 1.08 30.74 ± 0.35 30.95 ± 0.75 30.86 ± 0.88 29.81 ± 0.75* 30.51 ± 1.25
Glo (g/L) 24.30 ± 1.24 24.90 ± 1.69 26.58 ± 2.37 26.88 ± 1.35* 24.58 ± 1.43 25.85 ± 1.62 25.23 ± 1.63 25.79 ± 2.36
Alb/Glo 1.26 ± 0.03 1.23 ± 0.06 1.17 ± 0.07* 1.15 ± 0.05** 1.26 ± 0.06 1.2 ± 0.05 1.19 ± 0.05* 1.19 ± 0.06
Tbil (μmol/L) 2.14 ± 0.23 2.36 ± 0.15 2.06 ± 0.25 2.24 ± 0.45 2.22 ± 0.19 2.40 ± 0.21 2.39 ± 0.16 2.39 ± 0.21
Dbil (μmol/L) 0.80 ± 0.07 0.72 ± 0.08 0.78 ± 0.11 0.78 ± 0.08 0.82 ± 0.08 0.86 ± 0.09 0.85 ± 0.09 0.88 ± 0.10
Ibil (μmol/L) 1.34 ± 0.18 1.64 ± 0.09* 1.28 ± 0.25 1.46 ± 0.40 1.40 ± 0.15 1.54 ± 0.14 1.54 ± 0.09 1.51 ± 0.12
ALT (U/L) 56.20 ± 5.81 51.20 ± 5.36 65.80 ± 8.41 76.80 ± 33.07 49.17 ± 8.86 46.88 ± 6.33 48.13 ± 9.72 45.88 ± 3.40
AST (U/L) 204.40 ± 36.05 195.20 ± 33.52 202.60 ± 18.94 195.60 ± 60.80 159.50 ± 45.05 139.25 ± 33.78 135.25 ± 26.76 133.75 ± 23.87
AST/ALT 3.64 ± 0.51 3.88 ± 0.93 3.10 ± 0.35 2.66 ± 0.40* 3.23 ± 0.59 2.96 ± 0.47 2.85 ± 0.45 2.91 ± 0.46
GGT (U/L) 0.64 ± 0.49 0.28 ± 0.40 0.28 ± 0.40 0.46 ± 0.49 1.00 ± 0.00 0.55 ± 0.48 0.89 ± 0.32 1.00 ± 0.00
ALP (U/L) 414.00 ± 119.44 338.00 ± 38.86 353.60 ± 20.79 345.20 ± 34.54 363.33 ± 77.29 320.5 ± 68.26 308.75 ± 61.68 291.38 ± 46.15
TG (mmol/L) 1.53 ± 0.35 1.49 ± 0.40 1.73 ± 0.65 2.23 ± 1.88 1.77 ± 0.62 1.76 ± 0.65 1.16 ± 0.33 0.91 ± 0.25**
TC (mmol/L) 2.49 ± 0.36 2.25 ± 0.42 2.54 ± 0.43 3.06 ± 0.35* 2.19 ± 0.18 2.42 ± 0.28 2.24 ± 0.25 2.48 ± 0.22**
HDL-C (mmol/L) 0.78 ± 0.10 0.68 ± 0.14 0.73 ± 0.09 0.80 ± 0.22 0.71 ± 0.07 0.75 ± 0.10 0.69 ± 0.11 0.77 ± 0.07
LDL-C (mmol/L) 0.27 ± 0.05 0.26 ± 0.07 0.34 ± 0.13 0.48 ± 0.10** 0.20 ± 0.03 0.25 ± 0.04* 0.26 ± 0.03* 0.25 ± 0.05
Glc (mmol/L) 5.19 ± 0.41 5.94 ± 0.26** 5.28 ± 0.77 5.93 ± 0.37* 5.64 ± 0.68 5.46 ± 0.50 6.03 ± 0.61 6.00 ± 0.37
LDH (U/L) 1436.50 ± 141.95 1243.36 ± 255.38 910.08 ± 165.81** 683.84 ± 202.51** 1143.87 ± 415.51 1007.39 ± 324.97 790.78 ± 253.54 749.79 ± 285.97
BUN (mmol/L) 4.88 ± 0.86 4.74 ± 0.93 4.00 ± 0.64 5.01 ± 0.60 4.76 ± 0.62 4.92 ± 0.39 5.70 ± 0.52* 4.96 ± 0.69
Cn (μmol/L) 46.60 ± 1.14 45.40 ± 4.83 44.60 ± 0.55** 45.20 ± 1.92 44.67 ± 1.97 44.00 ± 1.85 43.75 ± 2.25 45.75 ± 2.66
BUN/Cn 0.11 ± 0.02 0.11 ± 0.01 0.09 ± 0.02 0.11 ± 0.02 0.11 ± 0.02 0.11 ± 0.01 0.13 ± 0.01* 0.11 ± 0.02
UA (μmol/L) 89.00 ± 15.81 124.60 ± 8.68** 145.60 ± 14.93** 154.40 ± 17.14** 96.17 ± 17.01 111.75 ± 18.97 132.88 ± 14.26** 122.25 ± 25.79*
TBA (μmol/L) 21.78 ± 7.62 21.44 ± 5.74 18.82 ± 5.01 30.98 ± 7.49 21.97 ± 7.26 24.01 ± 6.79 28.9 ± 19.12 23.93 ± 9.87
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respective NMR data sets were established to identify the 
metabolic difference between the groups. The OPLS-DA 
scores plots (left panels in Figs. 3, 4 and Additional file 1: 
Figures  S4–S7) give a significant (P < 0.05) separation 
between Fe@Si-NPs-treated groups and the correspond-
ing controls, and the volcano plots (right panels in Figs. 3, 
4 and Additional file  1: Figures  S4–S7) offer an insight 
into the types of metabolites responsible for the separa-
tion. These metabolites provide the biochemical changes 
in the different bio-compartments following the admin-
istration of Fe@Si-NPs. The detailed metabolic infor-
mation including the VIP values and coefficients from 
multivariate statistical analysis and the P-values from 
univariate statistical analysis was listed in Additional 
file 1: Tables S2–S5.
Metabolomics analysis of kidney metabolome
The overall characteristics of kidney metabolome were 
that the larger nanoparticle induced the more obvious 
changes of the metabolites both at 6 h p.d. and 48 h p.d. 
(Additional file 1: Table S2).
In renal homogenates, an increase of formate and nic-
otinamide levels and a decrease of NAD level were dis-
played in near all six treated groups (Additional file  1: 
Table  S2). These metabolites provide a sensitive indica-
tor of their involvement in toxic events induced by Fe@
Si-NPs. The increases of 3-methylhistidine, acetate, deox-
yguanosine, pyroglutamate, tyrosine and uridine diphos-
phate glucose levels, and the decrease of isobutyrate 
level (Additional file  1: Table  S2) were, to some extent, 
correlated with increasing of the size of the nanoparti-
cles, thus implying to be size-dependent. In addition, 
Fe@Si-NPs also exhibited some size-specific metabolic 
responses, in which the changes of 3-hydroxybutyrate, 
alanine, aspartate, cholate, choline, dihydrothymine, eth-
anol, ethanolamine and glucose were only for the small-
size group, deoxyuridine, fumarate, glutamate, histidine, 
quinone, uridine and urocanate only for the mid-size 
Fig. 2 Typical 1H NMR spectra of deuterated liver, lung, kidney and spleen extracts from a low-dosed rat at 6 h p. d. The regions of δ 6.0–10.0 (in 
the dashed box) in the spectra were magnified 20 times in vertical expansion compared with the corresponding regions of δ 0.5–6.0. Ace acetate, 
Ade adenosine, Ala alanine, AMP adenosine monophosphate, Asp aspartate, Bet betaine, Ch choline, Cr creatine, Cyt cytidine, DG deoxyguanosine, 
DMA dimethylamine, EA ethanolamine, Eth ethanol, For formate, Fum fumarate, G glycerol, Glg glycogen, α-Glc alpha-glucose, β-Glc beta-glucose, 
Glu glutamate, Gly glycine, GPC glycerophosphocholine, GSH glutathione, 2-HB 2-hydroxybutyrate, His histidine, Hx hypoxanthine, m-I 
myo-Inositol, IB isobutyrate, Ile isoleucine, Ino inosine, Lac lactate, Leu leucine, Lys lysine, 1-MH 1-methylhistidine, NA nicotinamide, NAD NAD+, 
NAG N-acetylglutamate, PC phosphocholine, PG pyroglutamate, Phe phenylalanine, Prop propionate, Qn quinone, Ser serine, Suc succinate, TMA 
trimethylamine, Tri trigonelline, Trp tryptophan, Tyr tyrosine, Ud uridine, val valine
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Fig. 3 OPLS-DA scores plots (left panels) and corresponding volcano plots (right panels) derived from the 1H NMR data of kidney, liver, lung, 
and spleen obtained from the pairwise groups at 6 h post-administration of mid-size Fe@Si-NPs. C and M represent the control group and the 
mid-size Fe@Si NPs group (around 20 nm in diameter), respectively; 6 represents 6 h post-treatment. Marked dots in color volcano plots represent 
metabolites with statistically significant differences. Keys for the assignments are shown in Additional file 1: Table S1
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Fig. 4 OPLS-DA scores plots (left panel) and corresponding volcano plots (right panels) derived from the 1H NMR data of kidney, liver, lung, and 
spleen obtained from the pairwise groups at 48 h post-administration of mid-size Fe@Si-NPs. C and M represent the control group and the mid-size 
Fe@Si NPs group (around 20 nm in diameter), respectively, 48 represents 48 h post-treatment. Marked dots in color volcano plots represent 
metabolites with statistically significant differences. Keys for the assignments are shown in Additional file 1: Table S1
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group, and AMP, glycerol, glycerophosphorylcholine, 
methylmalonate, pantothenate, threonine, trigonelline 
and valine only for the large-size group (Additional file 1: 
Table S2).
Metabolomics analysis of liver metabolome
The overall characteristics of liver metabolome were 
similar to those of kidney, namely, the larger nanopar-
ticles induced the more metabolite variations. Liver 
metabolomic recovery in the three treatment groups at 
48 h p.d. could be observed to a certain degree, though 
not complete, which offers some clues of the biochemi-
cal processing of Fe@Si-NPs in the body. However, no 
metabolite was classified as sensitive indicator. The 
increases of deoxyuridine, formate, glycogen, histidine, 
lysine, threonine, urocanate and glucose levels, and the 
decrease of lactate and tyrosine levels (Additional file 1: 
Table S3) were, to some extent, correlated with increas-
ing of the size of Fe@Si-NPs. Therefore these metabolites 
were classified as size-dependent indicators. In addi-
tion, Fe@Si-NPs also exhibited size-specific metabolic 
response, in which the changes of ethanolamine, glycerol, 
sarcosine, succinate, trigonelline, tryptophan and uridine 
were only for the small-size group, choline, deoxyguano-
sine, glutamine, nicotinamide, pyroglutamate, quinone 
and trimethylamine only for the mid-size group, and 
alanine, AMP, aspartate, ATP, isobutyrate, NADH, pico-
linate, valine and xanthine only for the large-size group 
(Additional file 1: Table S3).
Metabolomics analysis of lung metabolome
In the lung metabolomes, at 6  h p. d. the small-size of 
Fe@Si-NPs induced the most variations of metabolites 
compared with other sizes (Additional file  1: Table  S4). 
At 48 h p. d. the large-size of Fe@Si-NPs induced promi-
nent shift in metabolite profile (Fig.  4). Formate level 
was elevated in near all treated groups (Additional 
file  1: Table  S4), which made formate as the only sensi-
tive indicator for the lung toxic events induced by Fe@
Si-NPs. The increases of myo-inositol, propionate and 
vitamin K1 levels (Additional file  1: Table  S4) were, to 
some extent, correlated with increasing of the size of Fe@
Si-NPs. So these metabolites were size-dependent indica-
tors. In addition, Fe@Si-NPs also exhibited size-specific 
metabolic response in lung metabolome, in which the 
changes of creatine, glycerophosphorylcholine, glycogen, 
inosine, lactate and tryptophan were only for the small-
size group, ethanol only for the mid-size group, and 
1-methylhistidine, adenosine, glutamine, leucine, lysine, 
N-acetylglutamate and pyroglutamate only for the large-
size group (Additional file  1: Table  S4). The metabolite 
variations in the small- and mid-size groups were promi-
nently recovered after 48 h p. d. However, the metabolic 
pathways in large-size group got more seriously affected 
at 48 h p. d. than at 6 h p. d., which was consistent with 
the results of biodistribution that showed statistically sig-
nificant in the large-size group at 48 h p. d.
Metabolomics analysis of spleen metabolome
The metabolite variations of the spleen were severely 
affected by Fe@Si-NPs exposure. The overall metabo-
lomic characteristics were that the larger nanoparticles 
induced the more metabolite variations. The increases 
of formate, nicotinamide, pyroglutamate and trypto-
phan levels, and a decrease of glutamine level were dis-
played in near all six treated groups (Additional file  1: 
Table S5). Interestingly, isoleucine was decreased at 6 h. 
p.d. but increased at 48  h p. d. in spleen tissue (Addi-
tional file 1: Table S5). These metabolites were defined as 
sensitive indicators for the spleen toxicity of Fe@Si-NPs. 
The elevation of aspartate, dihydrothymine, glutathione, 
N-acetylglutamate, pantothenate, and phenylalanine 
levels, and the reduction of 3-hydroxybutyrate, cre-
atine, ethanol, NAD and serine levels (Additional file  1: 
Table S5) were, to some extent, correlated with increasing 
of the size of the Fe@Si-NPs, implying that the changes of 
these metabolites were size-dependent. In addition, Fe@
Si-NPs also exhibited size-specific metabolic response, 
in which the changes of glycogen and NADP were only 
for the small-size group, alanine and ethanolamine only 
for the mid-size group, and acetate, AMP, glycerol, glyc-
erophosphorylcholine, malonate, myo-inositol, quinone, 
sarcosine, succinate, trimethylamine and glucose only for 
the large-size group (Additional file 1: Table S5).
Discussion
Correlation between nanoparticle sizes, biodistribution, 
and biological effects of Fe@Si‑NPs
The iron content in the kidneys was not significantly 
affected at 6 h p. d. in the different size groups, while at 
48 h p. d., the renal iron contents in the small- and large-
size groups displayed a significant increase to 176% and 
159% of the control, respectively. Previous research indi-
cated that small IONPs (10  nm) were more likely to be 
trapped in the liver and cleared from the kidneys [25]. 
In our study, the increased iron level in kidneys at 48 h 
p. d. in the small-size group would mean that 10 nm of 
Fe@Si-NPs were transported to the kidneys for excre-
tion. Another study indicated that the nanoparticles in 
about 40  nm in diameter are more readily taken up by 
endothelial cells and induce greater cytotoxicity than the 
smaller ones [28]. The increased iron level of large-size 
group in kidneys suggested the increased renal uptake of 
40  nm of Fe@Si-NPs at 48  h p. d. The observation that 
the more metabolites were affected by the large-size Fe@
Si-NPs exposure than that of small-size ones in renal 
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metabolome supported to the idea that the increased 
renal uptake of Fe@Si-NPs (40 nm), rather than increased 
excretion, accounted for the increased iron content in 
kidneys. Interestingly, the mid-size group showed no sig-
nificant accumulation of iron in the kidneys, suggesting 
that they possibly possess a long blood circulation time 
and thus are suitable as contrast agents for imaging.
All three sizes of Fe@Si-NPs were rapidly accumulated 
in spleen and liver at 6 h p. d., and the different sizes did 
not show fundamental differences. However, as contrast 
with the small-size group, the iron contents in mid- and 
large-size groups displayed a significant decrease at 48 h 
p. d. This discrepancy between iron content (positively 
correlated to nanoparticle concentration) and biologi-
cal/toxic effects implied that there are differences in the 
involved mechanisms, and the size effects play a role in 
determining the biological fate of Fe@Si-NPs.
Liver clearance involves both reticuloendothelial sys-
tem cells (Kupffer cells) and non-phagocytic hepatocytes. 
Particles ingested by Kupffer cells frequently remain 
within the cells, while particles taken up by hepatocytes 
can be eliminated by excretion. Most importantly, hepat-
ocytes represent a potential site for toxicity [29]. There-
fore, we suppose that small-size Fe@Si-NPs would be 
more readily ingested by phagocytic cells such as Kupffer 
cells, and showed a slow turnover; but the mid- and large-
size Fe@Si-NPs would be mainly taken up by hepatocytes 
and showed more toxicity. The results of the metabo-
lomic analysis indirectly support this conclusion, namely, 
the liver in the small-size group was demonstrated with 
high iron content (217% of the control, Fig. 1) at 48 h p. 
d. but without significant side effects on metabolic path-
ways (Additional file  1: Table  S3). In the spleen, a simi-
lar discrepancy also existed to that of liver. Therefore we 
believe that the different sizes of Fe@Si-NPs were taken 
up by the different cell types, thus leading to the different 
turnover ratio and the toxic effects.
Correlation between nanoparticle sizes and NAD depletion
LDH is an important enzyme in cellular metabolism, 
and it is found in almost all of body’s cells and known 
as an enzyme that represents the viability of the cell. It 
catalyzes the reduction of pyruvate to lactate along with 
NADH to NAD. In clinical diagnosis, elevations in LDH 
activity in serum indicate tissue or cellular damage, which 
can be observed in myocardial infarction, liver disease, 
severe shock, anemia, muscular dystrophy, malignancies 
and hypoxia [30, 31]. The reduced LDH activity is usually 
harmless and can be caused by genetic mutations or other 
factors that can lower enzyme levels including reducing 
protein synthesis or increasing protein breakdown in the 
cell. The coenzyme NAD is necessary for LDH activity. 
In the absence of NAD, LDH couldn’t exert its catalytic 
activity. Thus there is a possibility that the coenzyme 
NAD deficiency in response to Fe@Si-NPs exposure is 
the cause of this negative correlation between LDH activ-
ity and Fe@Si-NPs sizes (Table 1, Fig. 5). This hypothesis 
was further corroborated by the results of metabolomic 
analysis, namely Fe@Si-NPs exposure led to a significant 
decrease of NAD levels and a rise of nicotinamide level 
(Additional file 1: Tables S2, S3 and S5, Figs. 3, 4 and 5). 
These two metabolites are reactant and product of NAD-
consuming reactions, respectively. ADP-ribosylations, 
which arise during DNA damage, repair, or recombina-
tion, are known to be major NAD-consuming reactions 
in cell [32]. However, the direct correlation between the 
properties of nanomaterials, such as size or amino func-
tionalization, and the regulation of NAD-producing or 
-consuming pathways needs to be further investigated. In 
addition, intracellular NAD is synthesized de novo from 
Trp via kynurenine pathway that accounts for about 95% 
of all tryptophan catabolism. Thus Trp is important for 
the maintenance of NAD level in body. The alterations of 
Trp (Additional file 1: Table S5, Fig. 4) in our study sug-
gest that there may be a close correlation between Fe@
Si-NPs exposure and NAD synthesis.
One of the most significant metabolic changes was 
the rise of formate following the administration of Fe@
Si-NPs. Formate can be produced from a variety of for-
mate precursors (serine, glycine, tryptophan, histidine, 
choline, methionine, cholesterol and branched chain 
fatty acids), and also participates in a number of bio-
synthetic pathways [33, 34]. Formate can be catalyzed 
by mitochondrial 10-formyl-tetrahydrofolate synthetase 
and incorporated into the folate dependent one-carbon 
pool as 10-formyl-tetrahydrofolate, which provides one-
carbon for the synthesis of nucleotides or other biologi-
cal compounds. This metabolic disposition may be the 
primary route for formate elimination. As a critical co-
factor for formate incorporating into one-carbon pool, 
folate deficiency would affect the production and turno-
ver of formate. Pigs subjected to a folate deficiency diet 
exhibited a significant decrease (55%) in the systemic for-
mate clearance [35]. Vitamin  B12 is at the intersection of 
the folate-mediated one-carbon pathway and the methio-
nine cycle. The conversion of 5-methyl-tetrahydrofolate 
back to tetrahydrofolate requires vitamin  B12. Vitamin 
 B12 deficiency can lead to a secondary folate deficiency 
(methyl-trap hypothesis) and finally the elevated plasma 
formate levels in rats [36].
Folate and vitamin  B12 play an important role in sup-
plying active methyl group for the detoxification of 
xenobiotics. Previous studies have shown that nanopar-
ticles caused dysfunction of the methionine cycle and 
induced global hypomethylation in HaCaT cell line [37, 
38]. In this study, we assume that Fe@Si-NPs exposure 
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resulted in an active methyl group depletion and dys-
function of folate-mediated one-carbon metabolism, and 
subsequently decreased the assimilation of formate to 
the folate one-carbon pool, thus causing formate accu-
mulation in tissues (Additional file 1: Tables S2–S5, Fig-
ures S4–S7, Figs. 3, 4, 5).
In addition, our knowledge of the catabolic fate of for-
mate is limited. Animals do not possess NAD-dependent 
formate dehydrogenase that can directly converse for-
mate into  CO2 [39]. It has been reported that tetrahydro-
folate-bound formyl group or formate can be catabolized 
to  CO2 by NADP-dependent 10-formyltetrahydro-folate 
dehydrogenase [40] or catalase [41]. However, the extent 
to which 10-formyltetrahydro-folate dehydrogenase and 
catalase play a role in formate removal is uncertain. Thus 
we cannot exclude the possibility that an unknown NAD/
NADP-dependent dehydrogenase exists for catalyzing 
the oxidation of formate to  CO2, and the coenzyme NAD 
deficiency caused by Fe@Si-NPs exposure prevents for-
mate breakdown, and leads to a rise of formate in tissues 
(Fig. 5).
One of the most noteworthy metabolic characteris-
tics is the positive correlation between serum uric acid 
level and Fe@Si-NPs sizes. As an important intermediate 
metabolite in purine catabolism, the regulation of serum 
uric acid level is a complex process involving hepatic 
production, renal and gut excretion. Xanthine oxidore-
ductase (XOR) is the rate limiting enzyme of uric acid 
synthesis, and its two forms, xanthine dehydrogenase 
(XDH) and xanthine oxidase (XO), can both convert 
xanthine to uric acid but via different electron accep-
tor, in which XDH prefers NAD and XO prefers  O2 [42]. 
Under an inflammatory or hypoxic condition, XDH can 
be converted into oxidase type. Furthermore, nicotina-
mide can be oxidized by the cytochrome P450 enzyme 
to nicotinamide N-oxide, which can subsequently be 
catalyzed by xanthine oxidase to transfer O from nico-
tinamide N-oxide to xanthine in the course of uric acid 
formation [43]. Therefore, we suppose that NAD(P) defi-
ciency would promote the conversion of XDH to XO, 
and the elevated nicotinamide level would stimulate the 
production of nicotinamide N-oxide. These two aspects 
may contribute to the increased production of uric acid. 
The bigger nanoparticles may induce more serious NAD 
deficiency and produce more nicotinamide, and subse-
quently more XO and more nicotinamide N-oxide, and 
eventually produce more uric acid. This may be one rea-
son for the positive correlation between level variation of 
uric acid and Fe@Si-NPs sizes (Table 1, Fig. 5).
In addition, formate is a precursor of purine synthe-
sis. The work by Meiser et  al. [44] using 13C-methanol 
to trace the fate of formate in  vivo demonstrated that 
13C can be incorporated into uric acid, a product in 
purine catabolism, or even faster than that into ATP. An 
increase of purine synthesis can effectively lower the cir-
culating formate levels. The elevations of formate in most 
Fig. 5 Schematic representation of the proposed mechanism for the in vivo size effects of Fe@Si-NPs on NAD depletion. Green arrows indicate 
up- or down-regulation; red arrows represent activation; broken arrow indicates less known mechanisms; red T bars represent inhibition. LDH 
lactate dehydrogenase, NAD nicotinamide adenine dinucleotide, NAM nicotinamide, NAM N-oxide nicotinamide N-Oxide, XO xanthine oxidase, XDH 
xanthine dehydrogenase
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treatment groups were observed in the metabolomic 
analysis (Figs. 3, 4, 5 and Additional file 1: Figures S4–S7, 
Tables S2–S5). Therefore, the accumulations of formate 
would also contribute to the rise of uric acid, as observed 
in serum biochemical analysis (Table 1, Fig. 5).
GSH mediated detoxification of Fe@Si‑NPs
Glutathione (GSH), a tripeptide made up of three amino 
acids—glycine, cysteine, and glutamate, is synthesized 
and metabolized via the γ-glutamyl cycle. GSH conjuga-
tion reaction plays a crucial role in detoxification against 
xenobiotics. The size-dependent increases of GSH levels 
in spleen (Additional file  1: Table  S5, Fig.  3) were asso-
ciated with the stimulated activities of GSH in response 
to the exposure of the bigger size Fe@Si-NPs. Consistent 
with this result, the levels of pyroglutamate, an interme-
diate in glutathione metabolism, were increased in kidney 
and spleen tissues in most treatment groups (Additional 
file  1: Tables S2 and S5, Figures  S5, S6 and Figs.  4). In 
GSH synthesis, both α-ketoglutarate and glutamine are 
sources of glutamate. Isoleucine is metabolized by branch 
chain aminotransferase to glutamate via the reaction: 
isoleucine + α-ketoglutarate → glutamate + α-keto-β-
methyvaleric acid. Thus the changes of isoleucine, on the 
contrary to glutamate, were decreased in all treatment 
groups at 6 h p. d. but increased at 48 h p. d. in spleen 
(Additional file  1: Table  S5 and Fig.  3). In addition, we 
noticed that the levels of glutamine were decreased in 
nearly all treatment groups both at 6 h p. d. and at 48 h 
p. d. in spleen (Additional file 1: Table S5). The possible 
reason is that glutamine is not only a precursor to glu-
tamate (catalyzed by glutaminase) but also an important 
source for de novo purine synthesis. The rise of uric acid, 
a catabolite of purine metabolism, supports that de novo 
purine synthesis occurred actively (Table 1). These results 
suggest that GSH and its related enzymes play an impor-
tant role in the detoxification of Fe@Si-NPs.
Conclusions
In this study, we systematically explored the size effects 
on the in  vivo biodistribution and the potential toxic-
ity of amino-functionalized  Fe3O4@SiO2 nanoparticles 
in rats by untargeted metabolomic strategy. Our results 
indicate that (i) different sizes of Fe@Si-NPs induced 
different biological process and activities including bio-
distribution, biological effects and underlying mecha-
nisms; (ii) LDH, formate, uric acid, and GSH related 
metabolites were suggested as sensitive indicators for 
the size-dependent toxic effects of Fe@Si-NPs; (iii) 
NAD regulated LDH activity which was negatively cor-
related with Fe@Si-NPs sizes; (iv) Fe@Si-NPs induced 
the dysfunction of folate-mediated one-carbon metabo-
lism, thus causing the formate accumulation in tissues; 
(v) The bigger size of Fe@Si-NPs induce more xanthine 
oxidoreductase activities and produce more uric acid. 
(vi) GSH is important for the detoxification of Fe@
Si-NPs. Whether these toxic hypotheses are of gen-
eral significance will need further validation in a wide 
range of nanoparticles. However, our findings provide 
the ground for the size selection and optimization, fur-
ther contributing to the biological applications of Fe@
Si-NPs.
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